SCHEMBL1663843

SCHEMBL1663843

CC(C)c1nc2cc(O)ccc2c(=O)n1Cc1nc2ccccc2s1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AKR1B1 P15121 13/20 0.48
TRPV1 Q8NER1 1/20 0.45
KDM4E B2RXH2 3/20 0.44
MAPT P10636 3/20 0.44
ALDH1A1 P00352 2/20 0.44
LMNA P02545 2/20 0.44
GAA P10253 2/20 0.44
MEN1 O00255 1/20 0.44
POLB P06746 1/20 0.44
HTT P42858 1/20 0.44
KMT2A Q03164 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
SMN1; SMN2 Q16637 3/20 0.43
NPC1 O15118 2/20 0.43
RAB9A P51151 2/20 0.43
TP53 P04637 1/20 0.43
ALOX15 P16050 1/20 0.43
TSHR P16473 1/20 0.43
CASP1 P29466 1/20 0.43
HSD17B10 Q99714 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1663099 0.78 TRPV1 (0.47) TRPV1KDM4EMAPTALDH1A1LMNA
SCHEMBL1663885 0.78 ALOX5AP (0.52) TRPV1MAPTALDH1A1LMNAMEN1
SCHEMBL1663625 0.76 TRPV1 (0.50) AKR1B1TRPV1KDM4EMAPTALDH1A1
SCHEMBL1663421 0.75 TRPV1 (0.54) AKR1B1TRPV1ALDH1A1SMN1; SMN2NPSR1
SCHEMBL1664148 0.75 TRPV1 (0.54) AKR1B1TRPV1MAPTALDH1A1LMNA
SCHEMBL1663833 0.74 TRPV1 (0.47) TRPV1KDM4EMAPTALDH1A1GAA
SCHEMBL1663306 0.74 TRPV1 (0.51) AKR1B1TRPV1ALDH1A1L3MBTL1NPSR1
SCHEMBL1663509 0.74 TRPV1 (0.48) AKR1B1TRPV1KDM4EMAPTALDH1A1
SCHEMBL1666082 0.73 TRPV1 (0.47) AKR1B1TRPV1KDM4EMAPTALDH1A1
SCHEMBL1663990 0.73 TRPV1 (0.47) TRPV1KDM4EMAPTGAAMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2305652-A2 Trisubstituted quinazolinone derivatives as vanilloid antagonists Novartis AG (CH) 2011-04-06 EP disclosed
US-20090082365-A1 Trisubstituted Quinazolinone Derivatives as Vanilloid Antagonists NOVARTIS AG 2009-03-26 US disclosed
CN-101356160-A Trisubstituted quinazolinone derivatives as vanilloid antagonists JANSSEN PHARMACEUTICA NV (CH) 2009-01-28 CN disclosed
EP-1963283-A2 TRISUBSTITUTED QUINAZOLINONE DERIVATIVES AS VANILLOID ANTAGONISTS Novartis AG (CH) 2008-09-03 EP disclosed
WO-2007065662-A2 TRISUBSTITUTED QUINAZOLINONE DERIVATIVES AS VANILLOID ANTAGONISTS NOVARTIS AG (CH) 2007-06-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090082365-A1 Trisubstituted Quinazolinone Derivatives as Vanilloid Antagonists TRPV1, TRPV3, TRPV5 AKR1B1 1529/4885TRPV1 1/4885KDM4E 2742/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.